Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 350Polycystic Ovary Syndrome 38Endometrial Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 16Neoplasms 11Infertility 11Fallopian Tube Neoplasms 8Advanced Breast Cancer 8Triple Negative Breast Neoplasms 7Carcinoma, Intraductal, Noninfiltrating 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Recurrence 6Osteoporosis 6Carcinoma, Lobular 6Breast Diseases 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2

Interventions

pertuzumab 2Paclitaxel 2Neoadjuvant Therapy 2Docetaxel 2Carboplatin 2pyrotinib 1pegfilgrastim 1Trastuzumab 1Mastectomy, Modified Radical 1Letrozole 1Hydralazine 1Doxorubicin 1Cyclophosphamide 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Breast Cancer × Letrozole × Clear all
NCT05809024 2023-04-12

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Shandong Cancer Hospital and Institute

Phase 4 Unknown
100 enrolled
Breast

Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡